Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, colorectal 2

2343 - Consensus Molecular Subtypes (CMS) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: retrospective analysis of the MAX clinical trial


11 Sep 2017


Gastrointestinal tumours, colorectal 2


Jennifer Mooi


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


J. Mooi1, P. Wirapati2, R. Asher3, C. Lee3, P. Savas4, T.J. Price5, S. Tejpar6, J. Mariadason1, N. Tebbutt7

Author affiliations

  • 1 Oncogenic Transcription Laboratory, Olivia Newton-John Cancer Research Institute, 3084 - Heidelberg/AU
  • 2 Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Lausanne/CH
  • 3 Nhmrc Clinical Trials Centre, University of Sydney, Sydney/AU
  • 4 Medical Oncology, Peter MacCallum Cancer Center, Melbourne/AU
  • 5 Medical Oncology, Queen Elizabeth Hospital and University of Adelaide, 5011 - Woodville/AU
  • 6 Oncology, University Hospital Leuven, Leuven/BE
  • 7 Medical Oncology, Olivia Newton-John Cancer Centre and Austin Health, 3084 - Heidelberg/AU


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2343


CMS is a transcriptome-based classification of colorectal cancer (CRC) with prognostic implications, but its association with treatment outcomes, especially in the metastatic setting, remains unknown. We investigated whether CMS classification was predictive of bevacizumab treatment benefit using data from the phase 3 MAX trial. MAX previously reported progression-free survival (PFS) benefit for the addition of bevacizumab (B) to chemotherapy (capecitabine (C) +/- mitomycin (M)) in first line treatment of metastatic CRC.


Archival tumours from 256 patients (54% of trial population) were available for gene expression profiling using Almac Xcel microarray. Tumours were classified into CMS groups 1 to 4 using previously published methods. We correlated CMS groups with PFS in the MAX trial. The predictive value of CMS was demonstrated as the interaction between CMS and bevacizumab treatment, assessed by Cox proportional hazards model.


After data quality control, primary tumours from 239 patients (51% of trial population) were suitable for survival analysis. Distribution of CMS groups were CMS1 18%, CMS2 48%, CMS3 12%, CMS4 23%. Hazard ratios (HR)(95% CI) of PFS in C vs CB+CBM arms for CMS 1,2,3 and 4 were 0.83 (0.43-1.62), 0.50 (0.33-0.76), 0.31 (0.13-0.75) and 1.24 (0.68-2.25) respectively (test for interaction between CMS and treatment, p = 0.03). CMS remained a significant independent predictor of PFS after adjustment for prognostic factors in a multivariate analysis (p = 0.04).


In metastatic CRC, CMS 2 and 3 subtypes preferentially benefit from the addition of bevacizumab to chemotherapy, compared to CMS 1 and 4. Validation of these findings in independent cohorts is required. Once validated, CMS classification could be used to guide patient selection for bevacizumab therapy.

Clinical trial identification

Legal entity responsible for the study

Olivia Newton-John Cancer Research Institute, Australia


Olivia Newton-John Cancer Research Institute, Australia and Australian Gastrointestinal Trials Group (AGITG)


P. Wirapati: Funding: Roche, Bayer and Sanofi for research in predictive biomarker for colorectal cancer. T.J. Price, N. Tebbutt: Advisory boards: Roche All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.